Central Nervous System Pharmacology Practice Questions

Q: Which is the most potent analgesic agent?

Sufentanil. **Explanation:** The potency of an opioid analgesic is determined by its affinity for the **mu (μ) opioid receptors**. Among the synthetic phenylpiperidine derivatives (fentanyl congeners), **Sufentanil** is the most potent agent currently used in clinical practice. **Why Sufentanil is correct:** Sufentanil is approximately **5 to 10 times more potent than Fentanyl** and nearly **500 to 1,000 times more potent than Morphine**. Its high lipid solubility and high receptor affinity allow for rapid onset and intense analgesia, making it ideal for cardiac surgeries and as an adjunct in balanced anesthesia. **Analysis of Incorrect Options:** * **Fentanyl:** While highly potent (approx. 100 times more than morphine), it serves as the prototype for this class but is significantly less potent than its derivative, Sufentanil. * **Remifentanil:** Its potency is roughly equal to Fentanyl. Its unique feature is its metabolism by **plasma and tissue esterases**, leading to an ultra-short duration of action (half-life Fentanyl ≈ Remifentanil > Alfentanil > Morphine. 2. **Context-Sensitive Half-Life:** Remifentanil has the shortest context-sensitive half-life, making it the drug of choice for continuous infusions where rapid recovery is required. 3. **Alfentanil** has the fastest onset of action despite being less potent. 4. **Sufentanil** is associated with the highest risk of chest wall rigidity (Stiff Man Syndrome) if injected rapidly.

Q: Which of the following is NOT a long-established antiepileptic drug used in complex partial seizures?

Lamotrigine. **Explanation:** The classification of antiepileptic drugs (AEDs) is historically divided into **Older (First-generation)** and **Newer (Second-generation)** agents. This distinction is high-yield for NEET-PG as it dictates side-effect profiles and pharmacokinetic properties. **Why Lamotrigine is the correct answer:** Lamotrigine is classified as a **Newer (Second-generation) AED**, introduced in the 1990s. While it is highly effective for focal (complex partial) seizures and Lennox-Gastaut syndrome, it is not considered a "long-established" or "older" drug compared to the other options. **Analysis of Incorrect Options:** * **Carbamazepine:** Long considered the traditional **drug of choice (DOC)** for complex partial seizures. It is a classic sodium channel blocker and a prototype of the older generation. * **Phenytoin:** One of the oldest AEDs (introduced in 1938). It is a first-line agent for focal and generalized tonic-clonic seizures, known for its zero-order kinetics at high doses. * **Valproate:** A broad-spectrum older AED effective against almost all seizure types, including complex partial seizures, by enhancing GABAergic transmission and blocking sodium/T-type calcium channels. **High-Yield Clinical Pearls for NEET-PG:** * **Lamotrigine Side Effect:** Watch for **Stevens-Johnson Syndrome (SJS)**; the dose must be titrated slowly to minimize this risk. * **Drug of Choice:** While Carbamazepine was the traditional DOC for complex partial seizures, newer guidelines often favor **Levetiracetam** or **Lamotrigine** due to better tolerability and fewer drug interactions. * **Enzyme Induction:** Phenytoin and Carbamazepine are potent **enzyme inducers**, whereas Valproate is an **enzyme inhibitor**. Lamotrigine is metabolically neutral but its levels are doubled when co-administered with Valproate.

Q: Which of the following is a metabolite of carisoprodol?

Meprobamate. **Explanation:** **Carisoprodol** is a centrally acting skeletal muscle relaxant used for the relief of acute, painful musculoskeletal conditions. Its primary mechanism of action is mediated through its active metabolite, **Meprobamate**. 1. **Why Meprobamate is correct:** Carisoprodol is a carbamate derivative that undergoes extensive hepatic metabolism via the cytochrome P450 enzyme **CYP2C19**. The major metabolite produced is Meprobamate, which possesses sedative and anxiolytic properties. Meprobamate acts as a GABAA receptor modulator, contributing significantly to the muscle relaxant and sedative effects (and the high abuse potential) of carisoprodol. 2. **Why other options are incorrect:** * **Doxylamine:** An H1-antihistamine with potent sedative effects, commonly used as an over-the-counter sleep aid. It is not a metabolite of carisoprodol. * **Dimethadione:** The active metabolite of **Trimethadione**, an older anticonvulsant used for absence seizures. * **Amphetamine:** A potent CNS stimulant. While some drugs like Selegiline or Benzphetamine metabolize into amphetamines, carisoprodol does not. **High-Yield Clinical Pearls for NEET-PG:** * **Abuse Potential:** Due to its conversion to Meprobamate (a Schedule IV controlled substance), Carisoprodol has a high risk of misuse and physical dependence. * **Pharmacogenomics:** Patients who are "poor metabolizers" of **CYP2C19** will have higher serum levels of carisoprodol and lower levels of meprobamate, altering the clinical effect and toxicity profile. * **Withdrawal:** Abrupt cessation can lead to withdrawal symptoms similar to benzodiazepines or alcohol.

Q: Felbamate is used in the treatment of which condition?

Epilepsy. **Explanation:** **Felbamate** is a potent anticonvulsant medication primarily used in the management of **Epilepsy**. Its mechanism of action is unique and multi-modal: it acts as a potent antagonist at the glycine-binding site of the **NMDA (N-methyl-D-aspartate) receptor**, thereby inhibiting excitatory neurotransmission. It also modulates GABA-A receptors and blocks voltage-gated sodium channels. * **Why Option A is correct:** Felbamate is specifically indicated for refractory partial seizures in adults and as an adjunctive treatment for **Lennox-Gastaut Syndrome** (a severe childhood-onset epilepsy) in children. * **Why Options B, C, and D are incorrect:** While some antiepileptics (like Pregabalin for anxiety or SSRIs for depression/social phobia) have cross-over uses in psychiatry, Felbamate has no clinical role in treating Anxiety, Social Phobia, or Depression. Its severe side-effect profile limits its use strictly to intractable epilepsy. **High-Yield Clinical Pearls for NEET-PG:** * **Black Box Warning:** Felbamate is notorious for two life-threatening adverse effects: **Aplastic Anemia** and **Acute Hepatic Failure**. * **Clinical Utility:** Due to these toxicities, it is considered a **third-line drug**, reserved only for patients who do not respond to other medications and where the benefit of seizure control outweighs the risk of bone marrow or liver failure. * **Monitoring:** Patients on Felbamate require frequent monitoring of Complete Blood Count (CBC) and Liver Function Tests (LFTs).

Q: Which of the following 5-HT receptors is not a G-protein coupled receptor?

5-HT3. ### Explanation The correct answer is **5-HT3**. **1. Why 5-HT3 is the correct answer:** Serotonin (5-HT) receptors are categorized into seven families (5-HT1 to 5-HT7). Among these, the **5-HT3 receptor** is the only exception that is a **ligand-gated ion channel** (ionotropic receptor) [2]. It is a pentameric selective cation channel that, when activated, leads to the rapid depolarization of neurons via the influx of Na⁺ and K⁺ ions [1]. It is primarily located in the Area Postrema (Chemoreceptor Trigger Zone - CTZ) and the gastrointestinal tract [3]. **2. Why the other options are incorrect:** * **5-HT1:** These are G-protein coupled receptors (GPCRs) linked to **Gi/o** proteins, which inhibit adenylyl cyclase and decrease cAMP levels [1], [2]. * **5-HT2:** These are GPCRs linked to **Gq/11** proteins, which activate the phospholipase C (PLC) pathway, leading to increased IP3 and DAG [1]. * **5-HT4:** These are GPCRs linked to **Gs** proteins, which stimulate adenylyl cyclase and increase cAMP levels [1]. (Note: 5-HT5, 5-HT6, and 5-HT7 are also GPCRs). **3. High-Yield Clinical Pearls for NEET-PG:** * **Antiemetics:** 5-HT3 antagonists (e.g., **Ondansetron**, Granisetron) are the drugs of choice for chemotherapy-induced nausea and vomiting (CINV) [3]. * **Prokinetics:** 5-HT4 agonists (e.g., **Prucalopride**, Tegaserod) are used to treat chronic constipation as they stimulate the peristaltic reflex [3]. * **Migraine:** 5-HT1B/1D agonists (**Triptans**) are used for acute migraine attacks by causing cranial vasoconstriction. * **Mnemonic:** Remember "**3 is Free**" (as in free-flowing ions) or "**3 is the odd one out**" to recall that 5-HT3 is the only ionotropic serotonin receptor.

Q: Which of the following drugs is associated with neural tube defects?

Valproic acid. **Valproic acid** is the correct answer because it is the antiepileptic drug (AED) most strongly associated with **Neural Tube Defects (NTDs)**, specifically spina bifida [1, 2]. The underlying mechanism involves the inhibition of **histone deacetylase** and interference with **folate metabolism**, which are critical for proper neural tube closure during the first trimester (specifically the first 28 days of gestation). The risk of NTDs with Valproate is approximately 1–2%, which is significantly higher than the general population. **Analysis of Incorrect Options:** * **Ethosuximide (A):** Primarily used for absence seizures. While no drug is 100% safe in pregnancy, it is not classically associated with NTDs; its primary side effects are GI distress and lethargy. * **Lamotrigine (C):** Considered one of the **safest** AEDs during pregnancy. It has a much lower risk of major congenital malformations compared to Valproate. * **Topiramate (D):** While teratogenic, it is specifically associated with an increased risk of **oral clefts (cleft lip/palate)** rather than neural tube defects. **High-Yield Clinical Pearls for NEET-PG:** * **Folate Supplementation:** To mitigate risks, women of childbearing age taking AEDs should take high-dose folic acid (4–5 mg/day) pre-conceptionally. * **Fetal Hydantoin Syndrome:** Associated with **Phenytoin**, characterized by craniofacial dysmorphism, hypoplastic nails/phalanges, and IUGR. * **Drug of Choice:** For absence seizures, Ethosuximide is preferred; however, if tonic-clonic seizures coexist, Valproate is the drug of choice (except in pregnancy). * **Avoidance:** Valproate should be avoided in women of childbearing potential unless no other alternative is effective.

Q: Which of the following vitamins should not be supplemented in a patient with parkinsonism on levodopa therapy?

Pyridoxine. **Explanation:** **1. Why Pyridoxine (Vitamin B6) is the correct answer:** Levodopa is a precursor to dopamine that must cross the blood-brain barrier (BBB) to be effective. However, it is susceptible to **peripheral decarboxylation** by the enzyme **DOPA decarboxylase**. Pyridoxine acts as a vital **cofactor** for this enzyme. When a patient takes supplemental Pyridoxine, it accelerates the peripheral conversion of Levodopa into Dopamine. Since Dopamine cannot cross the BBB, this leads to two negative outcomes: * **Reduced Efficacy:** Less Levodopa reaches the brain, worsening parkinsonian symptoms. * **Increased Side Effects:** High levels of peripheral dopamine cause systemic effects like nausea, vomiting, and cardiac arrhythmias. *Note: This interaction is only clinically significant when Levodopa is used alone. If Levodopa is combined with a peripheral decarboxylase inhibitor like **Carbidopa**, this interaction is largely abolished.* **2. Why other options are incorrect:** * **Thiamine (B1), Cobalamine (B12), and Pantothenic acid (B5):** These vitamins do not serve as cofactors for DOPA decarboxylase. They do not interfere with the pharmacokinetics or pharmacodynamics of Levodopa and are safe to supplement if clinically indicated. **3. NEET-PG High-Yield Pearls:** * **The "Carbidopa" Rule:** Carbidopa does not cross the BBB; it inhibits peripheral decarboxylation, thereby increasing the half-life of Levodopa and allowing for a 75% dose reduction. * **Vitamin B6 & Levodopa:** This is a classic "Drug-Vitamin Interaction." * **Dietary Tip:** Patients on Levodopa should also avoid high-protein meals simultaneously with their medication, as neutral amino acids compete with Levodopa for transport across the BBB.

Q: Which of the following is NOT a side effect of phenytoin?

Microcytic anemia. **Explanation:** Phenytoin is a widely used antiepileptic drug known for its narrow therapeutic index and a distinct profile of side effects. **Why Microcytic Anemia is the Correct Answer:** Phenytoin does **not** cause microcytic anemia. Instead, it is characteristically associated with **Megaloblastic Anemia** (a type of macrocytic anemia). This occurs because phenytoin interferes with the absorption and metabolism of dietary folate, leading to folate deficiency. **Analysis of Incorrect Options:** * **A. Gum Hypertrophy:** This is a classic side effect occurring in about 20% of patients. It is caused by the overgrowth of gingival tissue due to increased expression of platelet-derived growth factor (PDGF). * **B. Hirsutism:** Phenytoin can cause excessive hair growth, particularly in young females, making it a less desirable choice for this demographic. * **C. Osteomalacia:** Phenytoin induces hepatic microsomal enzymes (CYP450), which increases the metabolism of Vitamin D. This leads to hypocalcemia and secondary hyperparathyroidism, resulting in osteomalacia (softening of bones). **High-Yield Clinical Pearls for NEET-PG:** To remember Phenytoin side effects, use the mnemonic **"HOT MALAI"**: * **H** – Hirsutism, Hypertrophy of gums * **O** – Osteomalacia * **T** – Teratogenicity (Fetal Hydantoin Syndrome: cleft lip/palate, digital hypoplasia) * **M** – Megaloblastic anemia * **A** – Ataxia * **L** – Lymphadenopathy (Pseudolymphoma) * **A** – Arrhythmias (on rapid IV injection) * **I** – Insulin inhibition (leading to hyperglycemia) **Note:** Phenytoin follows **Zero-order kinetics** (saturation kinetics) at therapeutic concentrations, meaning a small dose increase can lead to a disproportionate rise in plasma levels and toxicity.

Question 1

Which is the most potent analgesic agent?

Accepted Answer

Sufentanil

Answer

Fentanyl

Answer

Remifentanil

Answer

Allentanil

Question 2

Which is the most toxic antiepileptic drug?

Accepted Answer

Carbamazepine

Answer

Phenytoin

Answer

Valproate

Answer

Lamotrigine

Question 3

Which of the following is NOT a long-established antiepileptic drug used in complex partial seizures?

Accepted Answer

Lamotrigine

Answer

Valproate

Answer

Carbamazepine

Answer

Phenytoin

Question 4

Which of the following is a metabolite of carisoprodol?

Accepted Answer

Meprobamate

Answer

Doxylamine

Answer

Dimethadione

Answer

Amphetamine

Question 5

Felbamate is used in the treatment of which condition?

Accepted Answer

Epilepsy

Answer

Anxiety

Answer

Social phobia

Answer

Depression

Question 6

Which of the following 5-HT receptors is not a G-protein coupled receptor?

Accepted Answer

5-HT3

Answer

5-HT1

Answer

5-HT2

Answer

5-HT4

Question 7

Which of the following drugs is associated with neural tube defects?

Accepted Answer

Valproic acid

Answer

Ethosuximide

Answer

Lamotrigine

Answer

Topiramate

Question 8

Which of the following vitamins should not be supplemented in a patient with parkinsonism on levodopa therapy?

Accepted Answer

Pyridoxine

Answer

Thiamine

Answer

Cobalamine

Answer

Pantothenic acid

Question 9

Which of the following is NOT a side effect of phenytoin?

Accepted Answer

Microcytic anemia

Answer

Gum hypertrophy

Answer

Hirsutism

Answer

Osteomalacia

Question 10

Which anticonvulsive agent would be MOST appropriate as first-line therapy for a 21-year-old woman recently diagnosed with complex partial seizures?

Accepted Answer

Lamotrigine

Answer

Carbamazepine

Answer

Topiramate

Answer

Phenytoin

Central Nervous System Pharmacology — MCQs

Central Nervous System Pharmacology — MCQs

On this page

Practice by Chapter

Want unlimited practice?